Drug Profile
Atuliflapon - AstraZeneca
Alternative Names: AZD-5718Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Amides; Antiasthmatics; Cardiovascular therapies; Pyrans; Pyrazines; Pyrazoles; Small molecules; Urologics; Vascular disorder therapies
- Mechanism of Action 5-lipoxygenase activating protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma
- Discontinued Cardiovascular disorders; Coronary artery disease; Renal failure
Most Recent Events
- 29 Nov 2022 Discontinued - Phase-I for Cardiovascular disorders (In volunteers) in United Kingdom (PO) before November 2020 (AstraZeneca pipeline, November 2022)
- 30 Sep 2022 Discontinued - Phase-I for Coronary artery disease (In volunteers) in United Kingdom (PO) as per company decision (AstraZeneca pipeline, November 2022)
- 30 Sep 2022 Discontinued - Phase-I for Coronary artery disease (In volunteers) in USA (PO) as per company decision (AstraZeneca pipeline, November 2022)